Lilly to Showcase Data from its Alzheimer's Disease Portfolio at the Alzheimer's Association International Conference

Eli Lilly and Company has announced that 23 presentations will be given at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark from 12–17 July 2014. Of particular interest are three oral presentations being highlighted by the Alzheimer's Association via a "reporter tips sheet" or a "featured research session" that may provide important insights to physicians, and increase knowledge through basic research that could inform future clinical research trials:

• Combination Therapy with a Plaque Specific Abeta Antibody and BACE Inhibitor Results in Dramatic Plaque Lowering in Aged PDAPP Transgenic Mice (Sun., July 13, 4:00 p.m. - 5:30 p.m. CEST, Auditorium 15). This study provides basic research to support the possibility of using combination therapy to achieve maximal removal of beta-amyloid pathology, a possible cause of Alzheimer's disease.

• Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease (Tues., July 15, 8:30 a.m. - 10:00 a.m. CEST, Auditorium 15). This study evaluates the relationship between cognitive and functional decline in mild Alzheimer's disease. 

        ♦ Also to be presented during a Poster Session (P2-390), Mon., July 14, 11:45 a.m. - 2:15 p.m.CEST

• Effect of Amyloid Imaging on Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criterion (Wed., July 16, 2:15 p.m. - 3:45 p.m. CEST, Hall C5 A). This study looks at whether patients who meet the Appropriate Use Criteria (AUC) would be more likely to receive different care if they had a beta-amyloid imaging scan as part of their diagnostic work-up, compared to patients who do not meet the AUC.

Lilly will also present a poster, "Delayed-Start Analyses of Solanezumab Phase 3 EXPEDITION Studies in Mild Alzheimer's Disease," (Poster [P4-172], Wed., July 16, 11:45 a.m. - 2:15 p.m. CEST), which will compare effects among delayed-start and early-start treatment groups.

"We are pleased to have a strong scientific presence at this year's AAIC, highlighting our continued commitment to research and sharing key learnings with the Alzheimer's disease community as a whole," said Eric Siemers, MD, senior medical director of Lilly's Alzheimer's disease team. "The coming together of the scientific community at this meeting is crucial as the prevalence of the disease continues to rise with over 44 million people around the world with dementia, set to reach over 75 million by 2030."[1]

Reference

1. www.alz.co.uk/research/GlobalImpactDementia2013.pdf